Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

Senator Requests GAO Study of Drug Shortages

Monday, March 14, 2011

Senator Richard (Dick) Blumenthal (D-CT) sent a letter to the Government Accountability Office (GAO) requesting an investigation of drug shortages. In his letter, Senator Blumenthal requests that the GAO investigation “examine the extent of hospital shortages of pharmaceutical products and the prevalence of these shortages in recent years, the impact of such shortages on patient care, possible explanations, and potential legislative or administrative approaches to addressing this problem.” The letter follows Senator Amy Klobuchar’s (D-MN) introduction of S.296, the “Preserving Access to Life-Saving Medications Act.”

ASA supports a GAO investigation into drug shortages. ASA agrees with Senator Blumenthal that, “Patient access to a stable and reliable source of life-saving medicine is incredibly important, and the federal government should give all due attention to efforts to address these shortages.”

ASA continues to take a leadership role in addressing drug shortages. In November, ASA co-convened a Drug Shortages Summit with relevant stakeholders to examine the root causes of drug shortages as well as potential action that can be taken to alleviate the suffering to patients caused by these shortages. ASA’s lobby team has met with the staff of a number of federal lawmakers, including Senator Blumenthal’s staff, to discuss the implications of the drug shortages for anesthesiologists.

Click here to visit ASA’s webpage dedicated to Drug Shortages.
Click here to read the letter Senator Blumenthal sent to the GAO requesting the investigation.

 

 

« Back to Washington Alerts